Clinical Outcomes and Risk Factors for Death in Critically Ill Patients with Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Treated with Ceftazidime-Avibactam: A Retrospective Study.

Authors:
Zhang L; Ma Y; Zhao C; Zhao S; Zhao L and 4 more

Journal:
Infect Drug Resist

Publication Year: 2024

DOI:
10.2147/IDR.S445243

PMCID:
PMC10824611

PMID:
38293316

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Infect Drug Resist

Abbreviation: Infect Drug Resist

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Infectious Diseases

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Antifungal Selection for the Treatment of Onychomycosis: Patient Considerations and Outcomes.
Axler E; Lipner SR. (2024) - Transparency Score: 3/6
Antimicrobial Resistance of <i>Clostridioides difficile</i> in Children from a Tertiary Pediatric H…
Li X; Wang Y; Cao R and 6 more (2024) - Transparency Score: 4/6
Antimicrobial Resistance Patterns of Staphylococcus Aureus Isolated at a General Hospital in Vietna…
An NV; Hai LHL; Luong VH and 14 more (2024) - Transparency Score: 3/6
Antimicrobial Use-Related Problems Among Hospitalized Pediatric Patients: A Prospective Observation…
Gidey K; Aregawi SG; Hailu BY and 2 more (2024) - Transparency Score: 3/6
Association Studies of Serum Levels of TNF- α, IL-10, IFN-γ and CXCL 5 with Latent Tuberculosis Inf…
Razbek J; Daken M; Chen Y and 7 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure The authors report no conflicts of interest in this work."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025